Evidence map›Paper›PMID 35540106›Full record

ArticleJHEP reports : innovation in hepatology2022

Molecular characterization of chronic liver disease dynamics: From liver fibrosis to acute-on-chronic liver failure.

Isabel Graupera, Laura Isus, Mar Coll, Elisa Pose, Alba Díaz, Julia Vallverdú, Teresa Rubio-Tomás, Celia Martínez-Sánchez, Patricia Huelin, Marta Llopis and 6 more

Open access · goldAbstract read
In one paragraph

Article in JHEP reports : innovation in hepatology, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 21 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
21citing papers in PubMed, 1 pooled it
5.6field-weighted citation impact, top 3% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

21 citing papers in PubMed, 1 synthesis or guideline pooled it, 38 citations in OpenAlex.

  1. Pooled it
  2. Article
  3. Review
  4. Article
  5. Review
  6. Review
  7. Article
  8. Article
  9. Article
  10. Article
  11. Loss ofJHEP reports : innovation in hepatology · 2025
    Article
  12. Article
  13. Review
  14. Article
  15. Article
  16. Article
  17. Article
  18. Article
  19. Review
  20. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

16 authors at 6 institutions in 1 country.

Isabel GrauperaLiver Unit, Hospital Clínic, Barcelona, Catalonia, Spain.
Laura IsusInstitute for Research in Biomedicine (IRB Barcelona) and The Barcelona Institute of Science and Technology. Barcelona, Catalonia, Spain.
Mar CollInstitut d'Investigacions Biomèdiques August Pi i Sunyer (IDIBAPS), Barcelona, Catalonia, Spain.
Elisa PoseLiver Unit, Hospital Clínic, Barcelona, Catalonia, Spain.
Alba DíazPathology Service, Hospital Clinic-IDIBAPS, Barcelona, Spain.
Julia VallverdúInstitut d'Investigacions Biomèdiques August Pi i Sunyer (IDIBAPS), Barcelona, Catalonia, Spain.
Teresa Rubio-TomásInstitut d'Investigacions Biomèdiques August Pi i Sunyer (IDIBAPS), Barcelona, Catalonia, Spain.
Celia Martínez-SánchezInstitut d'Investigacions Biomèdiques August Pi i Sunyer (IDIBAPS), Barcelona, Catalonia, Spain.
Patricia HuelinLiver Unit, Hospital Clínic, Barcelona, Catalonia, Spain.
Marta LlopisInstitut d'Investigacions Biomèdiques August Pi i Sunyer (IDIBAPS), Barcelona, Catalonia, Spain.
Cristina SoléLiver Unit, Hospital Clínic, Barcelona, Catalonia, Spain.
Constantino FondevilaDept. of General and Digestive Surgery, Hospital Universitario La Paz, IdiPAZ, CIBERehd, Madrid, España.
Juan José LozanoCentro de Investigación Biomédica en Red de Enfermedades Hepáticas y Digestivas (CIBERehd), Barcelona, Catalonia, Spain.
Pau Sancho-BruInstitut d'Investigacions Biomèdiques August Pi i Sunyer (IDIBAPS), Barcelona, Catalonia, Spain.
Pere GinèsLiver Unit, Hospital Clínic, Barcelona, Catalonia, Spain.
Patrick AloyInstitute for Research in Biomedicine (IRB Barcelona) and The Barcelona Institute of Science and Technology. Barcelona, Catalonia, Spain.
Hospital Clínic de Barcelona · ESConsorci Institut D'Investigacions Biomediques August Pi I Sunyer · ESCentro de Investigación Biomédica en Red de Enfermedades Hepáticas y Digestivas · ESHospital Universitario La Paz · ESInstitució Catalana de Recerca i Estudis Avançats · ESInstitute for Research in Biomedicine · ES

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Background & Aims: The molecular mechanisms driving the progression from early-chronic liver disease (CLD) to cirrhosis and, finally, acute-on-chronic liver failure (ACLF) are largely unknown. Our aim was to develop a protein network-based approach to investigate molecular pathways driving progression from early-CLD to ACLF. Methods: Transcriptome analysis was performed on liver biopsies from patients at different liver disease stages, including fibrosis, compensated cirrhosis, decompensated cirrhosis and ACLF, and control healthy livers. We created 9 liver-specific disease-related protein-protein interaction networks capturing key pathophysiological processes potentially related to CLD. We used these networks as a framework and performed gene set-enrichment analysis (GSEA) to identify dynamic gene profiles of disease progression. Results: Principal component analyses revealed that samples clustered according to the disease stage. GSEA of the defined processes showed an upregulation of inflammation, fibrosis and apoptosis networks throughout disease progression. Interestingly, we did not find significant gene expression differences between compensated and decompensated cirrhosis, while ACLF showed acute expression changes in all the defined liver disease-related networks. The analyses of disease progression patterns identified ascending and descending expression profiles associated with ACLF onset. Functional analyses showed that ascending profiles were associated with inflammation, fibrosis, apoptosis, senescence and carcinogenesis networks, while descending profiles were mainly related to oxidative stress and genetic factors. We confirmed by qPCR the upregulation of genes of the ascending profile and validated our findings in an independent patient cohort. Conclusion: ACLF is characterized by a specific hepatic gene expression pattern related to inflammation, fibrosis, apoptosis, senescence and carcinogenesis. Moreover, the observed profile is significantly different from that of compensated and decompensated cirrhosis, supporting the hypothesis that ACLF should be considered a distinct entity. Lay summary: By using transjugular biopsies obtained from patients at different stages of chronic liver disease, we unveil the molecular pathogenic mechanisms implicated in the progression of chronic liver disease to cirrhosis and acute-on-chronic liver failure. The most relevant finding in this study is that patients with acute-on-chronic liver failure present a specific hepatic gene expression pattern distinct from that of patients at earlier disease stages. This gene expression pattern is mostly related to inflammation, fibrosis, angiogenesis, and senescence and apoptosis pathways in the liver.

Indexed as

ACLFACLF, acute-on-chronic liver failurebiomarkerCC, compensated cirrhosischronic liver diseaseCLD, chronic liver diseaseCRP, C-reactive proteinDC, decompensated cirrhosisDEGs, differentially expressed genesGSEA, gene set-enrichment analysesHCC, hepatocellular carcinomaHSC, hepatic stellate cellsKRT-18, keratin-18LDRN, liver disease-related protein-protein interaction networkNAFLD, non-alcoholic fatty liver diseasenetwork biologyPCA, principal component analysistemporal gene expression profile

Identifiers

PMID35540106
PMCPMC9079303
OpenAlexW4226055228

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.